DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional…
28 analysts rate DXCM Buy on consensus.
Consensus price target: $97.23 (+15.34% upside from $84.30)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Stern Sadie EVP Chief People & Culture Off | Oct 27, 2026 | Sale | 2,565 | $201.66K |
| Stern Sadie EVP Chief People & Culture Off | Sep 28, 2026 | Sale | 2,565 | $220.97K |
| Brown Michael Jon EVP Chief Legal Compliance Off | Sep 15, 2026 | Sale | 1,700 | $142.87K |
| AUGUSTINOS NICHOLAS director | Sep 15, 2026 | Sale | 6,539 | $549.54K |
| AUGUSTINOS NICHOLAS director | Sep 14, 2026 | Sale | 1,550 | $130.23K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $4.66B | +15.6% | $836.3M |
| 2024 | $4.03B | +11.34% | $576.2M |
| 2023 | $3.62B | +24.49% | $541.5M |
Stock data for DXCM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics